To our knowledge, this current study is the first cost-effectiveness analysis of palbociclib plus fulvestrant for the second-line treatment of HR+/HER2- advanced breast cancer from the Chinese healthcare system based on the newly published data. Here, ERBB2 is linked to breast carcinoma.